All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The SOT Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the SOT Hub cannot guarantee the accuracy of translated content. The SOT Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Solid Organ Transplant is an independent medical education platform, sponsored by Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Drug updates

VIEW ALL
Important announcement
🚨NEWS🚨 @EU_Commission grants orphan drug designation to MIC-LX, an investigational cell therapy, for living-donor #KidneyTransplantation following a positive opinion from the EMA COMP, with evaluation ongoing in the phase IIb TOL-2 trial. Read more: https://bit.ly/4yIoZwz
Important announcement
🚨NEWS🚨 @US_FDA approves centralized EVLP device for deceased-donor lung assessment before transplantation in adults with end-stage lung disease. Read more: https://bit.ly/44DRGwA
Important announcement
@HealthNYGov approves a blood-based #KidneyTransplant acute rejection test, establishing nationwide access in the US. Read more: https://bwnews.pr/4vvRRGb
Important announcement
China’s NMPA accepts new drug application for KJ103, an injectable recombinant IgG-degrading enzyme, for desensitization therapy in highly sensitized #KidneyTransplant recipients. Read more: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0604/2026060401573.pdf